EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.
2019 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.
Concin, N.; Lorusso, D.; Braicu, I.; Ray-Coquard, I. L.; Joly, F.; Harter, P. & Wimberger, P. et al. (2019)
Journal of Clinical Oncology, 37(15_suppl) pp. TPS5605-TPS5605. DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS5605
Documents & Media
Details
- Authors
- Concin, Nicole; Lorusso, Domenica; Braicu, Ioana; Ray-Coquard, Isabelle Laure; Joly, Florence; Harter, Philipp; Wimberger, Pauline; Lotz, Jean-Pierre; Zeimet, Alain G; Scambia, Giovanni; Schmalfeldt, Barbara; Zamagni, Claudio; Raspagliesi, Francesco; Mustea, Alexander; Ulmer, Hanno; Kramer, Daniela ; Dobbelstein, Matthias ; Pujade-Lauraine, Eric; Sehouli, Jalid; Vergote, Ignace
- Issue Date
- 2019
- Journal
- Journal of Clinical Oncology
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
